DavidHenry MichaelSteffinMDStem Cell Transplant/Immunotherapy

Pediatric Hematology & Oncology • Houston, TX

Assistant professor performing clinical research in Phase 1 CAR T cell trials for pediatric solid tumors, with a clinical focus in Hematopoietic Stem Cell Transplantation

Join to view full profile

Dr. Steffin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Steffin's full profile

Already have an account?

Office
6701 Fannin St Ste 1510
Clinical Care Center Texas Childrens Hospital
Houston, TX 77030
Phone+1 832-822-4242

Education & Training

Baylor College of MedicineFellowship, Pediatric Stem Cell Transplant, 2018 - 2019
Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 2015 - 2018
Maimonides Medical Center/Infants and Children's Hospital of BrooklynResidency, Pediatrics, 2012 - 2015
Technion-Israel Inst of Technology Faculty of MedicineClass of 2012

Certifications & Licensure

TX State Medical License 2015 - 2026
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors Start of enrollment: 2021 Dec 08
RECRUITING
PHASE1

Publications & Presentations

PubMed

Cardiovascular Complications of Immune Effector Cell Therapies in Pediatric Hematological and Solid Tumors.
Aaron B Ross, Kriti Puri, Thomas L Johnson, Lilliam D Correa, Tami D John
Pediatric Blood & Cancer. 2025-04-01
2 citations
Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma.
Che-Hsing Li, Sandhya Sharma, Andras A Heczey, Mae L Woods, David H M Steffin
Nature Medicine. 2025-02-17
7 citations
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers.
David Steffin, Nisha Ghatwai, Antonino Montalbano, Purva Rathi, Amy N Courtney
Nature. 2025-01-01

Lectures

A phase I clinical trial using armored GPC3 CAR T cells for children with relapsed/refractory liver tumors.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

From Bench to Bedside and Back: CAR T Cells Armed with IL-15 Show Promise in Treating Solid CancersJanuary 28th, 2025
Study Shows Long-Term Safety of Genetically Modified Immune Effector CellsMarch 31st, 2022